Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
This enabled successful estimation of TP53 penetrance for three LFS cancer types: breast (BR), sarcoma (SA), and others (OT), from 186 pediatric sarcoma families collected at MD Anderson Cancer Center.
|
31719101 |
2020 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
We have outlined nine bone and soft tissue sarcomas for which TP53 plays a crucial tumor suppressive role.
|
31276706 |
2019 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
Although neither of these two genes have been previously associated with sarcoma, ABCB5 has been shown to share clinical drug resistance associations with melanoma and leukaemia and C16orf96 shares regulatory elements with genes that are involved with TNF-alpha mediated apoptosis in a p53/TP53-dependent manner.
|
31053105 |
2019 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The sarcoma also harbored a somatic TP53 mutation: c.844C > T, p.R282W.
|
29315962 |
2018 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
In the absence of Kras mutations, injury of the muscle with global deletion of p53 results in sarcomas with amplification of chromosomal regions encompassing the Met or Yap1 gene.
|
30333301 |
2018 |
Sarcoma
|
1.000 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.
|
28338660 |
2017 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Synonymous mutation in TP53 results in a cryptic splice site affecting its DNA-binding site in an adolescent with two primary sarcomas.
|
28475293 |
2017 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
We performed whole-exome sequencing (WES) in a familial aggregation of three individuals affected with soft-tissue sarcoma (STS) without TP53 mutation (Li-Fraumeni-like, LFL) and found a shared pathogenic mutation in <i>CDKN2A</i> tumour suppressor gene.
|
28592523 |
2017 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
This approach has facilitated the identification of novel AT-rich interaction domain 1A gene mutations in ovarian clear cell carcinoma, frequent tumor protein 53 (<i>TP53</i>) gene mutations in high-grade ovarian serous carcinoma, and Kirsten rat sarcoma and B-rapidly accelerated fibrosarcoma proto-oncogene, serine/threonine kinase gene mutations in low-grade ovarian serous carcinoma.
|
28454214 |
2017 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
Many malignancies display amplification of MDM genes encoding negative regulators of p53 and therefore much effort to date has concentrated on the development of molecules that inhibit MDM2, the most advanced of which are being tested in clinical trials for sarcoma, glioblastoma, bladder cancer and lung adenocarcinoma.
|
28927521 |
2017 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The germline and somatic <i>TP53-</i>mutant variants were enriched in the transcriptomes for both sarcomas.
|
27683180 |
2017 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Sarcoma physicians (N = 124) from 21 countries participated, 40% of whom favored TP53 mutation testing in children regardless of family history, increasing to ∼83% for all age groups if a family history was present and ∼85% if multiple primary cancers were present.
|
26923110 |
2016 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
To investigate whether TP53 DNA mutational status impacts progression-free survival (PFS) in patients with advanced sarcomas (soft tissue sarcoma) treated with vascular endothelial growth factor receptors (VEGFR) inhibition.
|
26646755 |
2016 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
Nutlin inhibits TP53-MDM2 interaction and is under investigation in soft-tissue sarcomas (STS) and other malignancies.
|
26427052 |
2015 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Correlations of telomere length, P53 mutation, and chromosomal translocation in soft tissue sarcomas.
|
26191279 |
2015 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
Tumor cells were diffusely positive for p53 and focally positive for epithelial markers and EGFR, but were negative for thyroid transcription factor-1, suggesting an initial diagnosis of primary pleomorphic sarcoma.
|
26045851 |
2015 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
The aim of this study was to explore the efficacy and define mechanisms of action of PRIMA-1(MET) as a TP53 targeted therapy in soft-tissue sarcoma (STS) cells.
|
26463477 |
2015 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
This case identifies a possible role of p53 dysfunction in the dedifferentiation process of SFT as reported in other sarcomas.
|
25015562 |
2014 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The present meta-analysis of currently available data suggests that the p53 codon 72 polymorphism may not play a role in sarcoma development in Caucasians.
|
24449505 |
2014 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Known genetic events in these tumors are mutations in TP53 (atypical fibroxanthoma and pleomorphic dermal sarcoma) and RAS (pleomorphic dermal sarcoma) genes, often having a UV signature.
|
24030750 |
2014 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
Of these target genes, the GADD45A promoter region was shown to be hypermethylated in 82% of wild-type TP53 sarcomas that did not respond to Nutlin-3a, thereby providing mechanistic insight into the innate ability of sarcomas to resist apoptotic death following Nutlin-3a treatment.
|
24336067 |
2014 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
Genetic depletion of Snail1 in MSCs that are deficient in p53 tumor suppressor downregulates MSC markers and prevents the capability of these cells to originate sarcomas in immunodeficient SCID mice.
|
24947186 |
2014 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The mutation status of TP53 and expression of MDM2, TP53, and their genetic variants SNP309 and R72P (Arg72Pro) were investigated in 125 sarcoma patient samples and 18 sarcoma cell lines.
|
23165797 |
2013 |
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Germline alterations of the tumour suppressor TP53 gene are detected approximately in 25% of the families suggestive of Li-Fraumeni syndrome (LFS), characterised by a genetic predisposition to a wide tumour spectrum, including soft-tissue sarcomas, osteosarcomas, premenopausal breast cancers, brain tumours, adrenocortical tumours, plexus choroid tumours, leukaemia and lung cancer.
|
23612572 |
2013 |
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
Both Tp53(Δ11/+) and Tp53(Δ11/Δ11) rats developed a wide spectrum of tumors, most commonly sarcomas.
|
22917926 |
2013 |